Akihiro Yoshimura
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications
Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma.
Journal: Scientific reports
Published: April 02, 2026
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.
Journal: Anticancer research
Published: February 28, 2026
Myosteatosis Predicts Poor Prognosis in Patients With Castration-Resistant Prostate Cancer Treated With Enzalutamide.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: November 20, 2025
Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer.
Journal: iScience
Published: October 02, 2025
Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer.
Journal: Cancer science
Published: August 13, 2025
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.
Journal: Anticancer research
Published: July 08, 2025
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
Journal: International journal of clinical oncology
Published: May 05, 2025
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
Journal: Clinical lung cancer
Published: April 30, 2025
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.
Journal: Targeted oncology
Published: April 08, 2025
Last Updated: 09/26/2026